Athenagen Gains New AD Platform Via Zapaq Merger
Adding a new Alzheimer's disease platform to its portfolio, Athenagen Inc. agreed to merge with Zapaq Inc., a 5-year-old company focused on beta-secretase inhibitors. (BioWorld Today)
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.